Navigation Links
Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
Date:5/28/2009

Proteon also receives orphan drug designation for its lead product candidate, PRT-201

WALTHAM, Mass., May 28 /PRNewswire/ -- Proteon Therapeutics, Inc., announced today that it has completed a second closing of its Series B equity financing, securing an additional $12 million and increasing the total equity capital raised in this round to $50 million. The additional equity investment came primarily from two new investors, Bessemer Venture Partners and Devon Park Bioventures, as well as from previous investors. Proteon also disclosed its lead product candidate, PRT-201, received orphan drug designation from FDA for prevention of arteriovenous fistula (AVF) maturation failure and arteriovenous graft (AVG) failure in patients with end-stage renal disease who are on or preparing for hemodialysis. Orphan drug designation allows for certain tax credits and an extended period of data exclusivity. These new developments follow Proteon's recent announcement of an agreement with Novartis whereby Novartis has been granted an exclusive option to acquire Proteon following the successful completion of a Phase 2 clinical study of PRT-201, with a potential secondary right to a global license under pre-agreed conditions.

"We are very pleased and fortunate to add the outstanding firms of Bessemer and Devon Park to our existing syndicate of blue chip investors," said Timothy P. Noyes, President and CEO of Proteon.

The initial closing of the Series B financing in March included new investors MPM Bio IV NVS Strategic Fund L.P. and Vectis Healthcare & Life Sciences Fund, along with existing investors TVM Capital, Skyline Ventures, Prism VentureWorks, Intersouth Partners and several of Proteon's original angel investors. Earlier this year, Proteon initiated a Phase 1/2 human clinical study of PRT201 in patients undergoing surgery for AVF creation. The combination of the Novartis option agreement and the now increased size o
'/>"/>

SOURCE Proteon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
2. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
3. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
4. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
5. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
6. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
7. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
8. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
9. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
10. Cell Therapeutics Amends Modified Dutch Auction Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes
11. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources Group ... medical directors in the United States ... biosimilar market penetration will be the level of ... and the expected lower cost to patients. Payers ... that meet their pricing expectations in order to ...
(Date:7/30/2014)... July 30, 2014  The Chicago Bears are excited ... of Dermatology (Academy) in an effort to raise awareness ... will host free SPOT me™ skin cancer screenings at ... Soldier Field. SPOT me™ is an educational campaign ... dangers and risks of skin cancer, and encourages people ...
(Date:7/30/2014)... While administrative claims and other ... for a relatively long period of time, there ... use of these ‘big data’ for comparisons of ... today’s powerful computer technology with the plethora of ... holds significant promise for identifying optimal interventions for ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2
... The National Science Foundation,(NSF) has awarded Loma ... of $593,978 to lead a consortium in developing ... universities. Barry L. Taylor, Ph.D., Professor of Microbiology,and ... Affairs,will lead the project with Rohit Shukla, CEO ...
... - Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX:ONY) announced ... studies of PX-12 and preclinical studies of,PX-866 will ... American Association,for Cancer Research (AACR) in San Diego ... a Phase 1 clinical trial of PX-478,in patients ...
... Biopure,Corporation (Nasdaq: BPUR ) announced today that ... its independent auditor., The audit committee of ... review of audit firms that had expertise with ... in Boston, Massachusetts, Vitale, Caturano & Company, Ltd. ...
Cached Biology Technology:Loma Linda University Partners With Larta Institute for Technology Marketing Program 2Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 2Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 3
(Date:7/30/2014)... A team of biologists, led by Clemson University associate ... marine pest that will pave the way for novel ... bio-adhesives for medical and industrial applications. , The team,s ... examined the last larval stage of barnacles that attaches ... natural, possibly polymeric material that acts as an underwater ...
(Date:7/30/2014)... ranges and a changing climate threaten some of ... and so conservationists establish seed collections to save ... hopes of preserving some genetic diversity., For decades, ... models that offer a one-size-fits-all approach for how ... 50 seed samples regardless of species, pollination mode, ...
(Date:7/30/2014)... searching through a massive collection of 20-million-year-old amber found ... and the effort is yielding fresh insights into ancient ... the collection is fully curated, a task that will ... Dominican amber collection in the world, the researchers report. ... is that of a pygmy locust, a tiny grasshopper ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Saving seeds the right way can save the world's plants 2Decades-old amber collection offers new views of a lost world 2
... U.S. Department of,Homeland Security (DHS) announced today ... international visitors arriving at Boston,Logan International Airport ... department,s,upgrade from two- to 10-fingerprint collection to ... accurately and efficiently,establishing and verifying visitors, identities., ...
... About the Ocean Sciences Meeting News Media Registration ... 4 February 2008 Abstracts and Schedule Available Online Who,s ... This years meeting will offer a wealth of new ... it is found, from mountain peaks to deep ocean ...
... bring a combination of individual scientific skills, expertise ... these offer the opportunity to build a highly ... address the urgent need for bringing new antibiotic ... antibiotics and other antimicrobial agents have saved millions ...
Cached Biology News:DHS Begins Collecting 10 Fingerprints From International Visitors at Boston Logan International Airport 2Media advisory -- 2008 Ocean Sciences Meeting 2Media advisory -- 2008 Ocean Sciences Meeting 3Media advisory -- 2008 Ocean Sciences Meeting 4Unique fungal collection could hold key to future antibiotics 2Unique fungal collection could hold key to future antibiotics 3
... ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H 15 ... ,M.W.= 408.63 ,Assay: Greater than ... DMF) ,Biological Activity: Blue color with ... Agrees with theoretical values ,Thin Layer ...
Immunochemistry 1 & 2...
Vertical Rack (five box vapor phase rack), includes 2.0" (5.1cm) boxes...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Biology Products: